ClinicalTrials.gg
CompletedNCT06326606Updated Oct 9, 2024

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants

A Phase 1 interventional study of Psilocybin and Placebo in Healthy Volunteers, sponsored by MycoMedica Life Sciences PBC. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by MycoMedica Life Sciences PBC · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

MLS101 is being developed as a low dose psilocybin, that can be administered to treat various neurological and psychiatric conditions.

The purpose of this clinical trial is to assess how safe and tolerated MLS101 is; to see how MLS101 is distributed and cleared by the body (pharmacokinetics); and to assess the psychedelic effects of MLS101 in healthy adult participants.

Read the detailed description

In recent years, high-dose psilocybin has gained attention for its potential therapeutic benefits in many psychiatric indications, however existing clinical data for low psilocybin doses are limited.

Microdoses are generally considered to be those absent of profound sensory and cognitive effects that would interfere with normal everyday functioning, but only a small number of prospective studies have evaluated microdoses and/or low doses in a controlled manner.

As a foundational study of the therapeutic use of low doses of psilocybin, this study will evaluate the safety, tolerability, pharmacokinetics, and sensorial effects using a prospective, controlled, single ascending dose/multiple ascending doses in healthy volunteers.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

MycoMedica Life Sciences PBC is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Males or females aged 18 to 65 years old (inclusive) at the time of signing the form. Standard measures are required for this clinical trial.
  2. Healthy, in the opinion of the Investigator, based on prior (history of) or current (ongoing) medical and psychiatric screening assessments.
  3. Participants with no findings on physical examination, laboratory tests, and cardiac assessment.
  4. (BMI) within the range 18-32 kg/m2, inclusive.
  5. Normal blood pressure.
  6. Capable of giving signed informed consent which includes the requirements and restrictions as per the approved study protocol.

Key Exclusion Criteria:

  1. Prior known exposure to psilocybin within the past 10 years.
  2. Prior (history of) or current (ongoing) diagnosis, or first-degree relatives with clinically significant medical or psychiatric condition or disease.
  3. History of or presence of cardiovascular disease.
  4. Abnormal and clinically significant .
  5. History or presence of a neurodegenerative disorder such Alzheimer's disease or Parkinson's disease.
  6. Use of medications that have CNS effects or affect performance.
  7. Use of medications with serotonergic activity.
  8. History or presence of or idiosyncratic reaction to psilocybin or related compounds.
  9. History of substance or alcohol abuse disorder in the last 1 year.
  10. Participant who, for any reason, is deemed by the Investigator to be inappropriate for this study; or has any condition which would confound or interfere with the evaluation of the safety, tolerability, or PK of the drug; or is unable to comply with the study protocol.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    MLS101

    MLS101 capsule(s) administered orally as a once a day dose

    Drug: Psilocybin

  • Placebo comparator
    Placebo

    Active treatment matching capsules will be administered orally as a once a day dose

    Drug: Placebo

Interventions

  • Capsule containing active ingredient, psilocybin

    Also known as: MLS101

  • DrugPlacebo

    Capsule with no active ingredients

06

What researchers measure

Primary outcomes

  1. Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs)

    Time frame: Screening (Day -60) to end of study visit (Day 8)

  2. Occurrence of clinically significant changes in physical examination, vital signs, ECGs, clinical laboratory tests, the Columbia-Suicide Severity Rating Scale (C-SSRS).

    The Columbia Suicide Severity Rating Scale (C-SSRS) is a short questionnaire. If there is a positive result for suicidality on the C-SSRS after Screening (defined by a participant answering "yes" to questions 4 or 5 on the suicidal ideation portion of the C-SSRS), the participant will be evaluated by an Investigator or medically qualified Sub-investigator for continuation in the study. Participants with suicidal ideation or behavior (a "yes" answer at any time during treatment to any one of the ten suicidal ideation and behavior questions (Categories 1-10) on the C-SSRS) at any time during the study will be withdrawn from the study. If a participant becomes suicidal during the study, an Investigator or medically qualified Sub-investigator should provide the appropriate treatment to the participant.

    Time frame: Screening (Day -60) to end of study visit (Day 8)

Secondary outcomes

  1. Pharmacokinetics of MLS101: maximum observed serum concentration (Cmax)

    Time frame: Day 1 to Day 3 post-dose and end of study visit (Day 8)

  2. Pharmacokinetics of MLS10: area under the plasma concentration-time curve (AUC)

    Time frame: Day 1 to Day 3 post-dose and end of study visit (Day 8)

  3. Pharmacokinetics of MLS101: time corresponding to the occurrence of Cmax (tmax)

    Time frame: Day 1 to Day 3 post-dose and end of study visit (Day 8)

  4. Pharmacokinetics of MLS101: apparent terminal elimination half-life (t½)

    Time frame: Day 1 to Day 3 post-dose and end of study visit (Day 8)

  5. Pharmacokinetics of MLS101: apparent total systemic clearance after oral administration (CL/F)

    Time frame: Day 1 to Day 3 post-dose and end of study visit (Day 8)

  6. Pharmacokinetics of MLS101: apparent volume of distribution during the terminal phase (Vz/F)

    Time frame: Day 1 to Day 3 post-dose and end of study visit (Day 8)

  7. Sensorial effects of MLS101

    Using validated questionnaires, the nominal sensorial threshold dose of MLS101 will be identified. The nominal sensorial threshold dose is defined as the highest dose studied that is absent of clinically significant sensorial effects, and which would not interfere with the participant's ability to carry on with routine activities of daily living. Higher scores indicate presence of sensorial effects.

    Time frame: Day 1 post-dose and end of study visit (Day 8)

  8. Cognitive function

    Using validated questionnaires and tools, cognitive function will be assessed and scores will be summarized for each visit, including observed values and change from baseline to evaluate the effects of MLS101 on participants' cognitive function.

    Time frame: Pre-dose (Day -1), Day 1 post-dose and end of study visit (Day 8)

07

Study locations

1 site
  • CMAX Clinical Research Pty Ltd
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Jul 2024, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2024
First posted
Mar 22, 2024
StartActual
Mar 27, 2024
Primary completionActual
Jul 8, 2024
CompletionActual
Jul 8, 2024
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06326606
Lead sponsor
MycoMedica Life Sciences PBC
Responsible party
Sponsor
First posted
Mar 22, 2024
Start date
Mar 27, 2024
Primary completion
Jul 8, 2024
Completion
Jul 8, 2024
Last update
Oct 9, 2024

Study contacts

Sepehr Shakib
principal investigator · Principal Investigator at CMAX Clinical Research Pty Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion